vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $20.1M, roughly 1.4× Arteris, Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -42.2%, a 36.4% gap on every dollar of revenue. On growth, Arteris, Inc. posted the faster year-over-year revenue change (30.0% vs 4.6%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $3.0M). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs 21.8%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
AIP vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $27.5M |
| Net Profit | $-8.5M | $-1.6M |
| Gross Margin | 90.8% | 93.2% |
| Operating Margin | -42.0% | 23.5% |
| Net Margin | -42.2% | -5.9% |
| Revenue YoY | 30.0% | 4.6% |
| Net Profit YoY | -3.7% | 5.3% |
| EPS (diluted) | $-0.19 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $27.5M | ||
| Q3 25 | $17.4M | $26.3M | ||
| Q2 25 | $16.5M | $25.8M | ||
| Q1 25 | $16.5M | $23.4M | ||
| Q4 24 | $15.5M | $26.3M | ||
| Q3 24 | $14.7M | $21.7M | ||
| Q2 24 | $14.6M | $20.2M | ||
| Q1 24 | $12.9M | $18.5M |
| Q4 25 | $-8.5M | $-1.6M | ||
| Q3 25 | $-9.0M | $-30.4M | ||
| Q2 25 | $-9.1M | $-2.0M | ||
| Q1 25 | $-8.1M | $-3.5M | ||
| Q4 24 | $-8.2M | $-1.7M | ||
| Q3 24 | $-7.7M | $-2.9M | ||
| Q2 24 | $-8.3M | $-3.5M | ||
| Q1 24 | $-9.4M | $-1.8M |
| Q4 25 | 90.8% | 93.2% | ||
| Q3 25 | 89.9% | 92.9% | ||
| Q2 25 | 89.4% | 92.5% | ||
| Q1 25 | 90.8% | 92.2% | ||
| Q4 24 | 89.8% | 91.4% | ||
| Q3 24 | 90.1% | 90.8% | ||
| Q2 24 | 90.0% | 90.0% | ||
| Q1 24 | 88.7% | 89.8% |
| Q4 25 | -42.0% | 23.5% | ||
| Q3 25 | -50.1% | 11.2% | ||
| Q2 25 | -50.0% | -0.1% | ||
| Q1 25 | -46.6% | -8.9% | ||
| Q4 24 | -45.9% | 18.6% | ||
| Q3 24 | -53.8% | 3.6% | ||
| Q2 24 | -51.1% | -14.3% | ||
| Q1 24 | -70.5% | -8.3% |
| Q4 25 | -42.2% | -5.9% | ||
| Q3 25 | -51.6% | -115.5% | ||
| Q2 25 | -55.3% | -7.8% | ||
| Q1 25 | -49.1% | -15.1% | ||
| Q4 24 | -53.0% | -6.5% | ||
| Q3 24 | -52.2% | -13.2% | ||
| Q2 24 | -57.2% | -17.4% | ||
| Q1 24 | -72.6% | -9.5% |
| Q4 25 | $-0.19 | $-0.32 | ||
| Q3 25 | $-0.21 | $-3.40 | ||
| Q2 25 | $-0.22 | $-0.23 | ||
| Q1 25 | $-0.20 | $-0.41 | ||
| Q4 24 | $-0.19 | $-0.18 | ||
| Q3 24 | $-0.20 | $-0.34 | ||
| Q2 24 | $-0.22 | $-0.41 | ||
| Q1 24 | $-0.25 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $-14.6M | $5.9M |
| Total Assets | $115.0M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $16.6M | ||
| Q3 25 | $39.0M | $14.9M | ||
| Q2 25 | $38.0M | $17.0M | ||
| Q1 25 | $42.3M | $20.7M | ||
| Q4 24 | $43.8M | $15.9M | ||
| Q3 24 | $48.7M | $16.3M | ||
| Q2 24 | $45.8M | $6.2M | ||
| Q1 24 | $44.8M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $-14.6M | $5.9M | ||
| Q3 25 | $-11.4M | $6.1M | ||
| Q2 25 | $-7.5M | $35.4M | ||
| Q1 25 | $-4.8M | $36.7M | ||
| Q4 24 | $-1.2M | $39.4M | ||
| Q3 24 | $2.2M | $39.8M | ||
| Q2 24 | $5.3M | $41.7M | ||
| Q1 24 | $9.5M | $43.3M |
| Q4 25 | $115.0M | $72.9M | ||
| Q3 25 | $107.7M | $71.1M | ||
| Q2 25 | $106.9M | $98.8M | ||
| Q1 25 | $98.3M | $96.4M | ||
| Q4 24 | $106.1M | $88.1M | ||
| Q3 24 | $97.7M | $88.5M | ||
| Q2 24 | $96.4M | $73.4M | ||
| Q1 24 | $101.4M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $3.9M |
| Free Cash FlowOCF − Capex | $3.0M | $3.9M |
| FCF MarginFCF / Revenue | 15.1% | 14.0% |
| Capex IntensityCapex / Revenue | 0.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $3.9M | ||
| Q3 25 | $3.2M | $2.2M | ||
| Q2 25 | $-2.5M | $2.7M | ||
| Q1 25 | $2.9M | $-2.0M | ||
| Q4 24 | $-2.6M | $932.0K | ||
| Q3 24 | $1.1M | $2.1M | ||
| Q2 24 | $311.0K | $-1.4M | ||
| Q1 24 | $477.0K | $-1.6M |
| Q4 25 | $3.0M | $3.9M | ||
| Q3 25 | $2.5M | $1.1M | ||
| Q2 25 | $-2.8M | $902.7K | ||
| Q1 25 | $2.7M | $-3.7M | ||
| Q4 24 | $-2.7M | $859.9K | ||
| Q3 24 | $1.1M | $2.0M | ||
| Q2 24 | $264.0K | $-1.5M | ||
| Q1 24 | $281.0K | $-1.7M |
| Q4 25 | 15.1% | 14.0% | ||
| Q3 25 | 14.2% | 4.2% | ||
| Q2 25 | -17.2% | 3.5% | ||
| Q1 25 | 16.2% | -15.9% | ||
| Q4 24 | -17.3% | 3.3% | ||
| Q3 24 | 7.4% | 9.4% | ||
| Q2 24 | 1.8% | -7.3% | ||
| Q1 24 | 2.2% | -9.0% |
| Q4 25 | 0.7% | 0.3% | ||
| Q3 25 | 4.1% | 4.0% | ||
| Q2 25 | 2.2% | 6.8% | ||
| Q1 25 | 1.1% | 7.4% | ||
| Q4 24 | 0.3% | 0.3% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.3% | 0.3% | ||
| Q1 24 | 1.5% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
